BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AM-Pharma Holding BV Appoints Erik van den Berg as CEO


9/2/2011 10:26:28 AM

Bunnik, The Netherlands, 2 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, today announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company.

Bart Wuurman, who has led the company the past 4 years decided to take on a new challenge in his career.

Eric Claassen, Chairman of AM-Pharma, commented:

“Bart has made a distinctive contribution to the development of AM-Pharma and I would like to thank him for his efforts in turning AM-Pharma into a focused organization, and for his role in preparing a new round of upcoming financing for the company.”

Bart Wuurman, said:

“I am proud to have worked with the AM Pharma team during the past four years. In this period the team was able to generate key clinical data that supports further development of AM-Pharma’s product for an indication of high medical need.”

For more information, please contact:

Am-Pharma:

Erik van den Berg

CEO Am-Pharma

Tel: +31 (0)30 259 8838

For media enquiries:

College Hill Life Sciences

Dr Douglas Pretsell/Daniel Gooch

Tel: +44 (0)20 7866 7866

Email: AMP@collegehill.com

Notes for Editors

About AM-Pharma www.am-pharma.com

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of severe inflammatory diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in severe Ulcerative Colitis, AM-Pharma will replace bovine Alkaline Phosphatase with its proprietary recombinant form of human Alkaline Phosphatase. This recombinant material will be used in future trials and for commercialization.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->